Akero Therapeutics To Present Results From Phase 2b SYMMETRY Study Investigating Efruxifermin In Patients With Compensated Cirrhosis Due To NASH
Portfolio Pulse from Happy Mohamed
Akero Therapeutics, Inc. (NASDAQ:AKRO) will present the topline week 36 results from its Phase 2b SYMMETRY study on October 10. The study evaluates the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). The results will include histology and changes from baseline in non-invasive measures of fibrosis, glycemic control, and lipoproteins, as well as safety and tolerability.
October 09, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Akero Therapeutics is set to present the results of its Phase 2b SYMMETRY study on Efruxifermin for NASH patients. The results could potentially impact the company's stock depending on the outcome.
The results of the Phase 2b SYMMETRY study could potentially impact Akero Therapeutics' stock. Positive results could boost investor confidence and drive the stock price up, while negative results could have the opposite effect. However, it's uncertain how the market will react until the results are presented.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100